Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1137390

registered interest
date	08/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government whether a date has been set for Vertex pharmaceuticals, NICE and NHS England to convene a further meeting to discuss how the cystic fibrosis drug Orkambi can be made available to patients.
tabling member printed	Baroness Morgan of Huyton
uin	HL16997
answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16998 HL16999 question first answered 15/07/2019 10:23:54 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	2168 label Biography information for Baroness Morgan of Huyton

1137391

registered interest
date	08/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the impact of the lack of availability of Orkambi on patients with cystic fibrosis; and what plans they have to discuss this issue with (1) patients, and (2) other interested parties.
tabling member printed	Baroness Morgan of Huyton
uin	HL16998
answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16997 HL16999 question first answered 15/07/2019 10:23:54 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	2168 label Biography information for Baroness Morgan of Huyton

1137392

registered interest
date	08/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what plans the Secretary of State for Health and Social Care has to intervene in the ongoing negotiations between Vertex pharmaceuticals, NICE and NHS England on the price of the cystic fibrosis drug Orkambi to ensure that it is made available to patients as soon as possible.
tabling member printed	Baroness Morgan of Huyton
uin	HL16999
answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>NHS England and NHS Improvement is leading the negotiations with Vertex and has made a revised and improved offer to Vertex that would provide immediate funding for Orkambi and Symkevi in advance of a positive assessment by the National Institute for Health and Care Excellence (NICE), in addition to expanded access to Kalydeco which is already funded by the National Health Service for certain patients. No date has been agreed for a further meeting as of yet, however negotiations are ongoing between Vertex, NHS England and NHS Improvement and NICE.</p><p>Cystic fibrosis can have a devastating effect on the lives of those who suffer from it, and those close to them, and the Government wants to see patients access innovative treatments at a cost-effective price for the NHS. The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the NHS, and it is not for Ministers to intervene in this process. The Department’s approach remains to strongly urge Vertex to accept NHS England and NHS Improvement’s generous offer, but in the absence of a deal, we have asked NHS England and NHS Improvement to continue to explore all options to ensure patients can access treatments as soon as possible.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL16997 HL16998 question first answered 15/07/2019 10:23:54 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	2168 label Biography information for Baroness Morgan of Huyton

1137406

registered interest
date	08/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Shingles: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what plans they have to establish a GP-operated call/recall system to invite older people to receive the shingles vaccination.
tabling member printed	Baroness Walmsley
uin	HL17013
answer	answer is ministerial correction date of answer 19/07/2019 answer text <p>As outlined in both the NHS Long Term Plan and <em>Investment and evolution: a five-year framework for GP contract reform to implement The NHS Long Term Plan</em>, NHS England and NHS Improvement are currently undertaking a Review of vaccinations and immunisations. The Department would not wish to pre-empt the outcome of this Review. <em>Investment and evolution</em> sets out the purpose of the Review as being to:</p><p>- Ensure the system incentivises achievement of appropriate uptake rates for immunisations in line with national public health uptake rates;</p><p>- Reduce the administrative burden on general practices by simplifying the system if possible;</p><p>- Clarify what is expected on call/recall for immunisations delivered through the general practitioner (GP) contract;</p><p>- Address anomalies in the system that directly incentivise some vaccines but not others;</p><p>- Look at how we deal with outbreaks and catch-up programmes; and</p><p>- Consider whether we extend the list of chargeable travel vaccines.</p><p>Recommendations from the Review will be implemented through the 2020 and 2021 GP contracts.</p><p>A copy of <em>Investment and evolution: a five-year framework for GP contract reform to implement The NHS Long Term Plan</em> is attached.</p><p> </p> answering member printed Baroness Blackwood of North Oxford question first answered 19/07/2019 09:14:02 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name gp-contract-2019.pdf title Five Year framework for GP contract reform
tabling member	2547 label Biography information for Baroness Walmsley

1137409

registered interest
date	08/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Death
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the report by the Royal College of Physicians The National Review of Asthma Deaths, published on 6 May 2014; and what plans they have to implement that report's recommendations.
tabling member printed	Baroness Wheeler
uin	HL17016
answer	answer is ministerial correction date of answer 19/07/2019 answer text <p>The Department collaborated with the Royal College of Physicians on the National Review of Asthma Deaths and welcomed this report. Since its publication, significant improvements have been made in asthma care.</p><p> </p><p>Respiratory disease, including asthma, is a clinical priority within the NHS Long Term Plan, which aims to improve outcomes for patients through earlier diagnosis and increased access to treatments. The Respiratory Delivery Board will take forward respiratory proposals set out in the Plan by working with key partners.</p><p> </p><p>The National Health Service is supporting the national asthma audit programme which provides data on a range of indicators to show improvements and opportunities in asthma outcomes. NHS RightCare will be publishing an asthma toolkit later this year to support local commissioners and systems in delivering quality care. A best practice tariff for asthma, which aims to reduce variation in asthma care, is also in development.</p><p> </p><p>The current quality outcomes framework indicators for asthma are in consultation and changes for the annual review indicators may include data on asthma control; exacerbations; and written personalised action plans.</p><p> </p><p>As set out in the Long Term Plan, pharmacies in primary care networks will undertake medicine reviews for asthma patients. This will include education on inhaler use and uptake of dry powder and smart inhalers where clinically appropriate.</p><p> </p> answering member printed Baroness Blackwood of North Oxford question first answered 19/07/2019 09:14:58 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	4157 label Biography information for Baroness Wheeler

1137416

registered interest
date	08/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Accelerated Access Collaborative
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will list (a) the criteria and (b) the timelines for products to be considered in (i) the current and (ii) future review rounds of the Accelerated Access Collaborative.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	274540
answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>In October 2018, the Accelerated Access Collaborative (AAC) announced it was supporting the uptake of 12 high performing products, with the potential to improve the lives of up to 500,000 patients per year and save the National Health Service £30 million per year in England. All the products currently being supported by the AAC have been recommended by the National Institute for Health and Care Excellence, and therefore evidence on clinical benefits and cost savings were considered as part of the process.</p><p>The AAC board met on 26 June and had a positive discussion about future products and expects to announce further products later this year.</p><p>The AAC will consider the following areas of interest when determining which products to support:</p><p>- evidence of clinical and cost effectiveness;</p><p>- addressing significant unmet need;</p><p>- application to large populations or high budget impact; and</p><p>- enabling a novel mode of action or enabling significant changes to the care pathway.</p><p> </p><p> </p><p> </p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 15/07/2019 15:23:36 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4131 label Biography information for Jim Shannon

1137417

registered interest
date	08/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hospitals: Infectious Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans the Accelerated Access Collaborative has to prioritise products which help to control hospital-acquired infections.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	274541
answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>The Accelerated Access Collaborative (AAC) is interested in identifying and supporting strategically important products that will have the biggest impact on patient health outcomes and/or the delivery of National Health Service services. This may include those which help control hospital-acquired infections.</p><p>The AAC has already had made significant progress towards getting the best innovations to patients quicker and at a better cost for the NHS.</p><p>Since 2018, NHS England has been supporting SecurAcath and Plus Sutures, products designed to reduce infection rates, on the Innovation and Technology Payment programme. SecurAcath is a device to secure catheters that reduces the infection risk for patients with a peripherally inserted central catheter and has benefited over 80,000 patients. Seven trusts with higher than 4% surgical site infection rates have adopted Plus Sutures, a triclosan coated suture, with more trusts to be supported this year.</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 15/07/2019 15:26:22 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4131 label Biography information for Jim Shannon

1137418

registered interest
date	08/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Accelerated Access Collaborative
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what criteria the Accelerated Access Collaborative uses in relation to decision-making on (a) medicines, (b) diagnostic tools and (c) digital services.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	274542
answer	answer is ministerial correction date of answer 15/07/2019 answer text <p>The Accelerated Access Collaborative (AAC) is interested in supporting the most strategically important products that will have the biggest impact on patient health outcomes and delivery of National Health Service services.</p><p>When selecting products, the AAC will consider the following irrespective of innovation type (i.e. medicines, diagnostic tools, and digital products):</p><p>- evidence of clinical and cost effectiveness;</p><p>- addressing significant unmet need;</p><p>- application to large populations or high budget impact; and</p><p>- enabling a novel mode of action or enabling significant changes to the care pathway.</p><p>Further information is available at the following link:</p><p><a href="https://www.nice.org.uk/aac" target="_blank">https://www.nice.org.uk/aac</a></p><p> </p><p> </p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 15/07/2019 15:33:03 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4131 label Biography information for Jim Shannon

1137423

registered interest
date	08/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Clinical Priorities Advisory Group
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 2 April 2019 to Question 236381 on Clinical Priorities Advisory Group, what steps NHS England has taken to ensure that treatments awaiting review by the Clinical Priorities Advisory Group are not delayed by the closure of the Commissioning Support Programme.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	274546
answer	answer is ministerial correction date of answer 16/07/2019 answer text <p>Following agreement with the Department and industry as part of the 2019 Voluntary Scheme for Branded Medicines Pricing and Access (voluntary scheme), the National Institute for Health and Care Excellence (NICE) is now expected to undertake appropriate appraisal for all new active substances in their first indication, and extensions to their Marketing Authorisation to add a significant new therapeutic indication, except where there is a clear rationale not to do so. NICE expects to implement this expansion from April 2020. They will be in a position to start progressing topics through the NICE topic selection process from the summer of 2019.</p><p>The topics that would have been referred to the Commissioning Support Programme will now be routed to the appropriate appraisal programme instead.</p><p>Furthermore, NHS England advises that all policy propositions that were previously being developed by the Commissioning Support Programme have been handed over to the relevant committee, to bring them in line with the usual development process. This process is set out in ‘Methods: National Clinical Policies’ at the following link:</p><p><a href="https://www.england.nhs.uk/publication/methods-national-clinical-policies/" target="_blank">https://www.england.nhs.uk/publication/methods-national-clinical-policies/</a></p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 274547 question first answered 16/07/2019 14:49:59 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon

1137424

registered interest
date	08/07/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential effect on treatments in NHS England’s Clinical Commissioning Policy programme of the closure of the Commissioning Support Programme; and if he will make a statement.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	274547
answer	answer is ministerial correction date of answer 16/07/2019 answer text <p>Following agreement with the Department and industry as part of the 2019 Voluntary Scheme for Branded Medicines Pricing and Access (voluntary scheme), the National Institute for Health and Care Excellence (NICE) is now expected to undertake appropriate appraisal for all new active substances in their first indication, and extensions to their Marketing Authorisation to add a significant new therapeutic indication, except where there is a clear rationale not to do so. NICE expects to implement this expansion from April 2020. They will be in a position to start progressing topics through the NICE topic selection process from the summer of 2019.</p><p>The topics that would have been referred to the Commissioning Support Programme will now be routed to the appropriate appraisal programme instead.</p><p>Furthermore, NHS England advises that all policy propositions that were previously being developed by the Commissioning Support Programme have been handed over to the relevant committee, to bring them in line with the usual development process. This process is set out in ‘Methods: National Clinical Policies’ at the following link:</p><p><a href="https://www.england.nhs.uk/publication/methods-national-clinical-policies/" target="_blank">https://www.england.nhs.uk/publication/methods-national-clinical-policies/</a></p><p> </p><p><strong> </strong></p><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 274546 question first answered 16/07/2019 14:49:59 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon